2022 American Transplant Congress
Intermediate Term Outcomes of SGLT2 Inhibitors Amongst Diabetic Kidney Transplant Recipients
1Pharmacy, VCUHS, Richmond, VA, 2VCUHS, Richmond, VA
*Purpose: The use of Sodium Glucose Linked Transporter Inhibitors (SGLT-2i) among non-transplant diabetic patients with chronic kidney disease (CKD) has demonstrated reduced cardiovascular mortality, delayed…2022 American Transplant Congress
Cryptococcal Meningitis Presenting as SIADH in a Heart Transplant Recipient
Temple University Hospital, Philadelphia, PA
*Purpose: Cryptococcal meningitis is a potentially fatal invasive fungal infection in solid organ transplant recipients. Meningoencephalitis is the most common clinical manifestation of cryptococcal infection.…2022 American Transplant Congress
Outcomes of Simultaneous Kidney Pancreas Transplantation in Patients with Type-1 and Type-2 Diabetes Mellitus
*Purpose: Advantages for type-2 diabetes mellitus (T2DM) patients receiving simultaneous kidney-pancreas transplantation (SKPT) as compared to kidney transplantation are shorter waiting times and availability of…2022 American Transplant Congress
Steatosis Following Liver Transplantation for Nonalcoholic Steatohepatitis is Associated with a Higher Rate of Cardiovascular Complications
*Purpose: Cirrhosis secondary to Nonalcoholic Steatohepatitis (NASH) is projected to become the leading indication for liver transplantation (LT) worldwide. Objectives: to evaluate the prevalence of…2022 American Transplant Congress
Associations of Immunosuppression Regimen with Fracture Risk After Kidney Transplant in High-Risk Populations: Identifying Targets for Risk-Reduction
*Purpose: Disorders of bone and mineral metabolism frequently develop with advanced kidney disease, may be exacerbated by immunosuppression (ISx) after kidney transplant (KTx), and may…2022 American Transplant Congress
Sodium-Glucose Cotransporter 2 Inhibitors to Treat Diabetes Mellitus After Kidney Transplant
*Purpose: This study describes experience prescribing sodium-glucose cotransport 2 inhibitors (SGLT2i) after kidney transplant to evaluate safety and effectiveness.*Methods: This is a retrospective, institutional review…2022 American Transplant Congress
Recipient TIM4+ Macrophage is a Central Hub for Metabolic Homeostasis in Liver Transplantation: From Mouse-to-Human
*Purpose: Hepatic ischemia-reperfusion injury (IRI) is a major risk factor for early graft dysfunction and predisposes to rejection in orthotopic liver transplantation (OLT). Previous studies…2022 American Transplant Congress
Pegloticase for Uncontrolled Gout in Kidney Transplant Recipients: Provisional Data Report of a Multicenter, Open-Label, Efficacy and Safety Study
*Purpose: Gout in kidney transplant (KT) recipients can be severe and particularly challenging to manage. Pegloticase co-therapy with immunomodulators improved urate lowering therapy (ULT) response…2022 American Transplant Congress
Living Related Liver Transplantation for Children with Metabolic Diseases- The Earlier the Better
*Purpose: Metabolic defects in children are rare throughout the world, however if diagnosed too late they can cause severe neurological irreversible deterioration, eventually being fatal.…2021 American Transplant Congress
Insulin Secretion and Insulin Resistance Trajectories Over 1 Year After Kidney Transplantation: A Multicenter Prospective Cohort Study
Department of Surgery, Ajou University Medical School, Suwon, Korea, Republic of
*Purpose: We investigated the changing patterns of insulin secretion and resistance and risk factors contributing to the development of post-transplant diabetes mellitus (PTDM) in kidney…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 11
- Next Page »